[go: up one dir, main page]

NL300364I2 - Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie - Google Patents

Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie

Info

Publication number
NL300364I2
NL300364I2 NL300364C NL300364C NL300364I2 NL 300364 I2 NL300364 I2 NL 300364I2 NL 300364 C NL300364 C NL 300364C NL 300364 C NL300364 C NL 300364C NL 300364 I2 NL300364 I2 NL 300364I2
Authority
NL
Netherlands
Prior art keywords
pandemic
influenza
influenza strain
california
strain
Prior art date
Application number
NL300364C
Other languages
English (en)
Other versions
NL300364I1 (nl
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26826080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300364(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of NL300364I1 publication Critical patent/NL300364I1/nl
Publication of NL300364I2 publication Critical patent/NL300364I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NL300364C 1999-04-06 2008-11-13 Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie NL300364I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12791299P 1999-04-06 1999-04-06
US13283999P 1999-05-06 1999-05-06
PCT/US2000/009021 WO2000060050A2 (en) 1999-04-06 2000-04-05 Recombinant influenza viruses for vaccines and gene therapy

Publications (2)

Publication Number Publication Date
NL300364I1 NL300364I1 (nl) 2009-01-05
NL300364I2 true NL300364I2 (nl) 2017-08-03

Family

ID=26826080

Family Applications (2)

Application Number Title Priority Date Filing Date
NL300365C NL300365I2 (nl) 1999-04-06 2008-11-13 Geïnactiveerd split influenzavirus van influenzastam A/Indonesia/05/2005 (H5N1) (PR8-IBCDC-RG2), desgewenst van een influenzastam die verondersteld wordt nauwe gelijkenis te vertonen met een influenzastam die verantwoordelijk zal zijn voor een pandemieNIBRG-14
NL300364C NL300364I2 (nl) 1999-04-06 2008-11-13 Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL300365C NL300365I2 (nl) 1999-04-06 2008-11-13 Geïnactiveerd split influenzavirus van influenzastam A/Indonesia/05/2005 (H5N1) (PR8-IBCDC-RG2), desgewenst van een influenzastam die verondersteld wordt nauwe gelijkenis te vertonen met een influenzastam die verantwoordelijk zal zijn voor een pandemieNIBRG-14

Country Status (19)

Country Link
EP (4) EP2910629B1 (nl)
JP (3) JP5543048B2 (nl)
KR (1) KR100702275B1 (nl)
CN (2) CN1350578B (nl)
AT (2) ATE525461T1 (nl)
AU (1) AU4073300A (nl)
BR (1) BRPI0009580B8 (nl)
CA (2) CA2365526C (nl)
CY (2) CY1108520T1 (nl)
DE (6) DE60035778T2 (nl)
DK (3) DK1820853T3 (nl)
ES (3) ES2290024T3 (nl)
FR (1) FR11C0027I2 (nl)
HK (1) HK1214298A1 (nl)
IL (2) IL145702A0 (nl)
MX (1) MXPA01010082A (nl)
NL (2) NL300365I2 (nl)
PT (2) PT1185615E (nl)
WO (1) WO2000060050A2 (nl)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
DE60035778T2 (de) * 1999-04-06 2008-04-30 Wisconsin Alumni Research Foundation, Madison Rekombinante influenzaviren zur vakzinherstellung und gentherapie
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
GB9916794D0 (en) * 1999-07-16 1999-09-22 Isis Innovation In vitro virus reconstitution
EP1194580B2 (en) * 1999-07-14 2010-08-25 Mount Sinai School of Medicine of New York University In vitro reconstitution of segmented negative-strand rna viruses
NZ521840A (en) 2000-04-28 2004-11-26 St Development of a multi-plasmid pol I - pol II based system for the generation of infectious influenza RNA viruses from cloned DNA
ES2295175T3 (es) * 2000-06-23 2008-04-16 Wyeth Holdings Corporation Ensamblaje de particulas similares al virus (vlp) de la gripe de tipo salvaje y quimericas.
EP1862550A1 (en) * 2000-06-23 2007-12-05 Wyeth Holdings Corporation Assembly of wild-type and chimeric influenza virus-like particles (VLPs)
US7211378B2 (en) 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
EP3009507B1 (en) 2002-02-13 2020-06-24 Wisconsin Alumini Research Foundation Signal for packaging of influenza virus vectors
ES2526191T3 (es) * 2002-04-26 2015-01-08 Medimmune, Llc Método para producir virus influenza B infeccioso en cultivo celular
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
AU2004249133B2 (en) * 2003-05-28 2009-05-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
CA2529647C (en) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
ES2345492T3 (es) 2003-12-23 2010-09-24 Medimmune, Llc Sistema multiplasmido para la produccion del virus de la gripe.
FR2866031B1 (fr) * 2004-02-11 2012-10-19 David Francois Joseph Millet Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
ES2393492T3 (es) 2004-05-25 2012-12-21 Medimmune, Llc Variantes de hemaglutinina y neuraminidasa de influenza
MX2007005818A (es) 2004-11-19 2007-07-20 Wisconsin Alumni Res Found Vectores recombinantes de la influenza con unidades de transcripcion en tandem.
CA2593036A1 (en) 2004-12-08 2006-06-15 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
ES2395813T3 (es) 2004-12-24 2013-02-15 Abbott Biologicals B.V. Obtención de un virus de la gripe
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
PL1945252T3 (pl) * 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ568210A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
AP2911A (en) 2005-12-02 2014-05-31 Sinai School Medicine Chimeric Viruses presenting non-native surface proteins and uses thereof
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
CN101472941B (zh) 2006-03-31 2017-08-08 沃弗-威斯康星校友研究基金会 用于疫苗的高滴度重组流感病毒
WO2007146057A2 (en) * 2006-06-09 2007-12-21 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US7601356B2 (en) 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
US20080069821A1 (en) 2006-08-09 2008-03-20 Medimmune Vaccines, Inc. Influenza Hemagglutinin And Neuraminidase Variants
JP5954921B2 (ja) 2006-09-11 2016-07-20 ノバルティス アーゲー 卵を使用しないインフルエンザウイルスワクチンの作製
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
WO2008147496A2 (en) 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
JP5666905B2 (ja) 2007-06-18 2015-02-12 メディミューン，エルエルシー ヘマグルチニンポリペプチド中に変化を有するインフルエンザｂウイルス
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2045323A1 (en) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
CN101497877B (zh) * 2008-01-28 2012-09-05 河北摩百生物科技有限公司 流感全病毒减活疫苗重组体、其构建方法及应用
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
JP2011527581A (ja) 2008-07-11 2011-11-04 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
EP2329845A4 (en) 2008-08-18 2013-08-14 Kitasato Daiichi Sankyo Vaccine Co Ltd BIRD GRAPEVIRUS ANTIGEN AND BOOSTER IMMUNIZATION PROCEDURE FOR BIRD FLUID VACCINE IN COMBINATION WITH A MUCOSAL ADJUVAN WITH EFFICACY THROUGH ORAL ADMINISTRATION
EP2233568A1 (en) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
KR20110132373A (ko) 2009-02-10 2011-12-07 노파르티스 아게 유행병-연관 주에 대한 인플루엔자 백신 요법
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
US9278126B2 (en) 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
RU2535970C2 (ru) 2009-02-12 2014-12-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейраминидазы гриппа
WO2010125461A1 (en) 2009-04-27 2010-11-04 Novartis Ag Adjuvanted vaccines for protecting against influenza
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN103237890A (zh) 2010-06-02 2013-08-07 巴克斯特保健股份有限公司 用于产生rna 病毒的方法和辅助病毒
CN102220293B (zh) * 2011-05-26 2012-12-19 中国农业科学院上海兽医研究所 犬流感重组病毒及其制备方法和应用
WO2013032942A1 (en) 2011-08-26 2013-03-07 Yoshihiro Kawaoka Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
WO2013030176A2 (en) 2011-09-02 2013-03-07 Westfälische Wilhelms-Universität Münster Live attenuated influenza virus
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN104450695B (zh) * 2014-11-26 2017-08-25 扬州大学 A型流感病毒基因pcr扩增引物及其快速克隆方法
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
CN107921117B (zh) * 2015-06-10 2022-06-07 霍欧奇帕生物科技有限公司 Hpv疫苗
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
CN108027371B (zh) 2015-07-07 2020-08-18 思齐乐 流感效力试验
JP2018530314A (ja) 2015-08-28 2018-10-18 ウィスコンシン アルムニ リサーチ ファンデイション ウイルス様粒子からの感染性インフルエンザウイルスの生成
CA3014435C (en) 2016-02-19 2023-04-18 Wisconsin Alumni Research Foundation (Warf) Improved influenza b virus replication for vaccine development
WO2019046211A1 (en) * 2017-08-28 2019-03-07 Wisconsin Alumni Research Foundation NANOCAPSULES FOR THE ADMINISTRATION OF RIBONUCLEOPROTEINS
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
CN107964035B (zh) * 2017-12-06 2020-07-24 中国科学院微生物研究所 一种用于流感病毒的有限复制型黏膜免疫疫苗
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
WO2020041311A1 (en) 2018-08-20 2020-02-27 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
US11739303B2 (en) 2020-01-24 2023-08-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized NA
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5658772A (en) 1989-12-22 1997-08-19 E. I. Du Pont De Nemours And Company Site-specific recombination of DNA in plant cells
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
AU3760495A (en) * 1994-09-30 1996-04-26 Aviron Chimeric Influenza Virus And Electroporation Method
EP0704533A1 (en) * 1994-09-30 1996-04-03 Bayer Ag An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus
CN1200675A (zh) * 1995-10-20 1998-12-02 耶路撒冷希伯来语大学依苏姆研究开发公司 流感疫苗
US5994526A (en) * 1996-06-21 1999-11-30 Plant Genetic Systems Gene expression in plants
EP1035209A1 (en) * 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
DE60035778T2 (de) * 1999-04-06 2008-04-30 Wisconsin Alumni Research Foundation, Madison Rekombinante influenzaviren zur vakzinherstellung und gentherapie

Also Published As

Publication number Publication date
JP5543048B2 (ja) 2014-07-09
ES2533622T3 (es) 2015-04-13
CA2365526C (en) 2016-07-05
EP1820853A3 (en) 2007-10-03
MXPA01010082A (es) 2002-04-24
EP1185615A2 (en) 2002-03-13
KR20010113044A (ko) 2001-12-24
NL300365I1 (nl) 2009-01-05
ATE525461T1 (de) 2011-10-15
CN1350578B (zh) 2010-05-12
EP2345716B1 (en) 2015-01-14
JP2003528570A (ja) 2003-09-30
HK1214298A1 (en) 2016-07-22
BR0009580A (pt) 2002-01-02
JP6224645B2 (ja) 2017-11-01
ES2373405T3 (es) 2012-02-03
CN101851636A (zh) 2010-10-06
ATE368729T1 (de) 2007-08-15
EP1820853B1 (en) 2011-09-21
PT1185615E (pt) 2007-10-04
DE122008000014I1 (de) 2011-12-01
CN101851636B (zh) 2015-11-25
BRPI0009580B8 (pt) 2021-05-25
EP1820853A2 (en) 2007-08-22
JP2011182797A (ja) 2011-09-22
DK2345716T3 (en) 2015-02-09
DE60035778D1 (de) 2007-09-13
DK1820853T3 (da) 2011-12-19
IL145702A (en) 2010-04-15
EP2345716A1 (en) 2011-07-20
AU4073300A (en) 2000-10-23
DE122008000035I1 (de) 2009-05-20
CA2928263A1 (en) 2000-10-12
CY1108520T1 (el) 2014-04-09
NL300365I2 (nl) 2017-08-03
ES2290024T3 (es) 2008-02-16
KR100702275B1 (ko) 2007-03-30
JP5775351B2 (ja) 2015-09-09
NL300364I1 (nl) 2009-01-05
FR11C0027I2 (fr) 2021-12-31
DE122008000058I1 (de) 2009-05-07
EP2910629A1 (en) 2015-08-26
DE122011100037I1 (de) 2012-03-22
CA2365526A1 (en) 2000-10-12
DE60035778T2 (de) 2008-04-30
DK1185615T3 (da) 2007-11-05
FR11C0027I1 (fr) 2011-08-26
PT1820853E (pt) 2012-01-03
EP2910629B1 (en) 2018-09-19
CY1112140T1 (el) 2015-11-04
WO2000060050A2 (en) 2000-10-12
JP2015119735A (ja) 2015-07-02
EP1185615B1 (en) 2007-08-01
WO2000060050A3 (en) 2001-01-18
HK1148778A1 (zh) 2011-09-16
BR0009580B1 (pt) 2014-11-25
IL145702A0 (en) 2002-07-25
CN1350578A (zh) 2002-05-22
DE122008000061I1 (de) 2009-02-12

Similar Documents

Publication Publication Date Title
NL300364I2 (nl) Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie
NL300368I2 (nl) Geïnactiveerd split influenzavirus van influenzastam A/Indonesia/05/2005 (H5N1) (PR8-IBCDC-RG2), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie
BR0214750A (pt) Imidazoquinolinas tioéter substituìdas
ATE336249T1 (de) Sulfonamid- und sulfamid-substituierte imidazochinoline
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
BR0116026A (pt) Imidazoquinolinas substituìdas por tioéter
ATE337010T1 (de) Desinfizierende und solubilisierende steroidzusammensetzungen
BR0011448A (pt) Imidazoquinolinas substituìdas por amida
ATE359279T1 (de) Moschus-geruchsstoffe
AU2001238401A1 (en) Cold-adapted equine influenza viruses
AU3840101A (en) Cold-adapted equine influenza viruses
BR0111729A (pt) 1-aril-4-oxo-1,4-dihidro-3-quinolinacarboxamidas como agentes antivirais
BR0308660A (pt) C-17 espirolactonização e 6,7 oxidação de esteróides
IS8051A (is) Kladríbínefnablöndur til inngjafar um munn
DE69525659D1 (de) Grippe-impfstoff
CY1105798T1 (el) Στepοειδη, η παρασκευη τους, φαρμακευτικες συνθεσεις απο αυτα και χρησεις των ενωσεων
IL175558A0 (en) A universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma
GT200100093A (es) Pirazoles sustituidos como inhibidores de cinasa p38